Another 2,300 AstraZeneca jobs go but 'simplification will lead to growth', says Soriot
This article was originally published in Scrip
AstraZeneca has outlined its strategic plans under new CEO Pascal Soriot ahead of an investor briefing in New York later today (March 21). AstraZeneca's newly stated strategic priorities include restructuring its SG&A activities with resultant significant job losses, driving its on-market growth platforms in a bid to return to growth, and achieving "scientific leadership". On the latter front, the firm announced a $240 million upfront discovery alliance with small biotech company Moderna Therapeutics, which is focused on mRNAi.